Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in Adults
Public ClinicalTrials.gov record NCT03357614. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Prospective, Phase 3, Randomized, Multi-center, Double-blind, Double-dummy Study of Efficacy, Tolerability & Safety of Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Treatment of cUTI in Adults
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a prospective, phase 3, randomized, multicenter, double-blind, double-dummy study to compare the efficacy and safety of sulopenem followed by sulopenem-etzadroxil/probenecid versus ertapenem followed by ciprofloxacin for the treatment of complicated urinary tract infections (cUTI) in adults.
Study identification
- NCT ID
- NCT03357614
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,395 participants
Conditions and interventions
Conditions
Interventions
- Sulopenem Drug
- Sulopenem-Etzadroxil/Probenecid Drug
- Ertapenem Drug
- Ciprofloxacin Drug
- Amoxicillin-clavulanate Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 18, 2018 (Actual)
- Primary completion
- Dec 14, 2019 (Actual)
- Completion
- Dec 14, 2019 (Actual)
- Last update posted
- Dec 29, 2020
2018 – 2019
United States locations
- U.S. sites
- 15
- U.S. states
- 9
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Medical Facility | Bellflower | California | 90706 | — |
| Medical Facility | Chula Vista | California | 91911 | — |
| Medical Facility | La Mesa | California | 91942 | — |
| Medical Facility | La Palma | California | 90623 | — |
| Medical Facility | Torrance | California | 90502 | — |
| Medical Facility | Miami Lakes | Florida | 33014 | — |
| Medical Facility | Columbus | Georgia | 31904 | — |
| Medical Facility | Idaho Falls | Idaho | 83404 | — |
| Medical Facility | Boston | Massachusetts | 02111 | — |
| Medical Facility | Royal Oak | Michigan | 48073 | — |
| Medical Facility | Butte | Montana | 59701 | — |
| Medical Facility | Columbus | Ohio | 43214 | — |
| Medical Facility | Columbus | Ohio | 43215 | — |
| Medical Facility | Dallas | Texas | 75246 | — |
| Medical Facility | Houston | Texas | 77057 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03357614, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 29, 2020 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03357614 live on ClinicalTrials.gov.